Boan Biotech Officially Listed on the Main Board of SEHK

Shandong Boan Biotechnology Co., Ltd. (“Boan Biotech” or the “Company”), a subsidiary of Luye Pharma Group, was officially listed on the Main Board of the Stock Exchange of Hong Kong (“SEHK”) under the stock code 6955.HK at an offer price of HK$19.8 per share. The successful listing on SEHK marks the beginning of a new phase in the development of Boan Biotech, which will be empowered by capital to forge ahead with the goal of becoming a “leading global biopharmaceutical company”.

Ms. Jiang Hua, Chairlady of the Board and CEO of Boan Biotech, said: "Today's listing is another new starting point in the development of Boan Biotech. Since the founding of Boan Biotech, we have been aspiring to become a 'leading global biopharmaceutical company', not just based in China. We look forward to serving the unmet medical needs of patients around the world with high-quality biological drugs made in China soon, thus contributing to the health of human beings with our strength."

Mr. Liu Dianbo, Executive Chairman of Luye Pharma Group, said, “The ‘biopharmaceutical business strategy’ is one of the most important business strategies for the current and future development of Luye Pharma Group. We are pleased to see that, after years of accumulation, Boan Biotech has built up unique competitive advantages in the biological drug sector. We are very optimistic about the performance of Boan Biotech after its listing and will fully support its next phase of development by leveraging our group's profound industry experience. We also look forward to the continuous collaboration between Boan Biotech and other business segments of our group to implement our mission of ‘Professional technology serves human health’.”

 

Luye Pharma’s Innovative Drug Ruoxinlin® Launched in China

December 3, Luye Pharma Group  held an offline product launch conference in Shanghai, together with an online event, to announce the launch of Ruoxinlin® (Toludesvenlafaxine Hydrochloride Extended-Release Tablets) in China. Ruoxinlin® is China’s first class 1 innovative chemical drug independently developed locally for the treatment of Major Depressive Disorder (MDD) and protected by intellectual property rights. The drug provides a powerful new option for patients, bringing the treatment of MDD to a new level.

 

World’s First Denosumab Biosimilar Boyoubei® Launched in China

December 10, Boan Biotech, a subsidiary of Luye Pharma Group, today held an offline product launch conference in Shanghai, together with an online event, to announce the launch of Denosumab Injection (Boyoubei®) in China. Indicated for the treatment of osteoporosis in postmenopausal women at high risk of fractures, the drug can significantly reduce patients’ risk of vertebral, non-vertebral and hip fractures. Boyoubei® is the first denosumab biosimilar approved for marketing in the world, and its launch represents a milestone in the high-quality development of China’s biopharmaceutical industry. In addition to China, Boan Biotech is also developing Boyoubei® in Europe and the U.S., with plans to market the drug globally.

 

Always Front of Mind and Follow Your Heart - Mindfront Health Celebrates Its 3-Year Anniversary

Mindfront Health’s recently held a “Happy Day” in Shanghai, Guangzhou, Shenzhen and Xi’an to celebrate its 3-year anniversary. Ms. Liu Aona, Executive Chairperson of Luye Medical Group, Mindfront Health’s management and all staff joined the event offline and offline and shared the joy.

   

Early in the morning of the "Happy Day", Mindfront Koala family greeted the guests to the party and took photos with them. Then the guests wrote down their stories with, and best wishes for Mindfront Health on the “leaves” and made a beautiful wishing tree.

In Xi’an Hospital and Shanghai Clinic, our lovely Mindfront team shared their memories and unforgettable stories. A brand-new corporate video also showed the team's three years of trials and hardships, honours, and dreams.

Ms. Liu Aona, Executive Chairperson of Luye Medical Group and Chairperson of Mindfront Health, fully affirmed the achievements of the team in the past three years. She also thanked Luye Medical Group’s 18 mental health hospitals and clinics in Australia for their support in clinical, psychological and management techniques, as well as the joint, unremitting efforts to promote academic exchanges between China and Australia, which greatly contributed to the localization and development of evidence-based medical treatment in China. She said: “I hope that Mindfront Health will continue to give full play to its unique clinical advantages, provide patients with more systematic and efficient mental health services, and keep making contributions to China's mental health system.”
   
Mindfront Health has deployed 7 institutions in Shanghai, Guangzhou, Shenzhen and Xi'an, and has obtained Internet medical service qualifications, launching a self-developed Internet medical service platform.

In birthday song and the sweet taste of cakes, Mindfront teams across China had a lovely birthday party together.

   
 

After the award ceremony of "My Favorite Mindfront Element", it was group photo time!In the future, Mindfront Health will continue to uphold its sense of social responsibility, bringing mental health and happiness to Chinese people with professional and caring services.

 

Yantai Huayi Rehabilitation Hospital TCM Doctor's “Dujiu” Therapy Won a National Utility Patent

Recently, "A Disposable and Practical Airtight Dujiu Device" designed by Dr. Zhai Jiali, a doctor in the TCM Section of Yantai Huayi Rehabilitation Hospital, won a patent approved by the State Intellectual Property Office. This is a new breakthrough achieved by the hospital in the field of Chinese medicine scientific research through continuous improvement of various traditional Chinese medicine characteristic therapies; and the patent has been applied into clinical treatment.
 

According to Dr. Zhai, Dujiu, an external treatment method of traditional Chinese medicine (TCM), is an outcome of wisdom in health preservation that has been passed down since ancient China. Doctors usually bake acupoints with burning gingers and herbs in treating a great range of diseases such as seasonal allergic rhinitis.
 
In Chinese Medicine theory, winter is the best season for health preserving. Since Huayi Rehabilitation Hospital launched a basket of TCM health-preserving experience and treatments, lots of patients have been attracted to visit the hospital.